NCT03973671 Prospective Sample Collection for Cancer of Bladder
| NCT ID | NCT03973671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Urinary Bladder Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2020-05-29 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2020-05-29 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).
Eligibility Criteria
Inclusion Criteria: * who are aged between 18-90, * who are of male or female sex, * who give their informed consent to collect their clinical and pathological data, * who are planned to undergo TURBT for BC, * who are planned to undergo (salvage) radical cystectomy with or without an extended pelvic lymph node dissection, * who are planned to undergo tumor biopsy (from primary or metastatic tumor), * who are planned to undergo radical nephroureterectomy ± partial cystectomy or segmental ureterectomy, with or without a lymph node dissection, * who are planned to undergo endoscopic tumor biopsy or resection, * from whom metastases will be surgically removed. Exclusion Criteria: * patients who do not give their informed consent to collect their clinical and pathological data, * patients who withdraw their informed consent to use their clinical and pathological data, * patients who refuse the planned treatment, * women who are pregnant or have suspicion of pregnancy.
Contact & Investigator
Steven Joniau, MD, PhD
PRINCIPAL INVESTIGATOR
Assistant Professor
Frequently Asked Questions
Who can join the NCT03973671 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Urinary Bladder Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03973671 currently recruiting?
Yes, NCT03973671 is actively recruiting participants. Contact the research team at murat.akand@uzleuven.be for enrollment information.
Where is the NCT03973671 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT03973671 clinical trial?
NCT03973671 is sponsored by Universitaire Ziekenhuizen KU Leuven. The principal investigator is Steven Joniau, MD, PhD at Assistant Professor. The trial plans to enroll 300 participants.